Patent · US Expired

Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation

US3982020A · kind A · utility

12Cited by

1References

2Claims

0Family size

Assignee

Sandoz AG · CH

Inventors

William J. Houlihan · Baden-Baden, DE
Robert E. Manning · Chesterfield, US

Key dates

Filing date	Sep 5, 1972
Grant date	Sep 21, 1976
Priority date	—
Expiry date	Sep 5, 1992

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/155
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Substituted benzylidene hydrazines e.g. N-(4-phenylbenzylidene)-N'-amidino hydrazine and their use as hypoglycemic-antihyperglycemic agents, anti-obesity agents and anti-inflammatory agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.